Alternative strategies to vaccines based on live attenuated or inactivated pathogens are constantly being developed with an aim to increase safety without significant loss of immunogenicity. Among these, virus-like particles (VLPs) offer several valuable features and represent a very appealing model. The eight timely and in-depth chapters of this book have been contributed by leaders in the field and cover a range of current topics in VLP-based vaccine development and clinical assessment for a range of human infectious diseases.
